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Available online 7 February 2015Abstract The use of herbal medicines continues to expand rapidly across world and many people
show positive interest to use herbal products for their health. The safety of herbal supplements has
become a globally major concern in national and international health authorities due to increasing
adverse events and adulterations.
It is difﬁcult to analyze herbal products that cause adverse events due to lack of sufﬁcient infor-
mation and expertise. Inadequate regulatory measures, weak quality control system and uncon-
trolled distribution channels are some of reasons that enhance the informal pharmaceutical
market. In recent years, the unfulﬁlled desire for sex has been a subject that has aroused increasing
public interest with respect to improve sexual functions. The use of herbal medicines substantially
increased due to escalated prevalence and impact of sexual problems worldwide and estimates pre-
dicting the incidence to raise over 320 million by year 2025. The various reasons to use herbal sup-
plements in men may be due to experiencing changes in erectile dysfunction (ED) due to certain
medical conditions such as diabetes and hypertension and bodily changes as a normal part of life
and aging.
There is a lack of adequate evidence, no impetus to evaluate and absence of any regulatory obli-
gations to undertake rigorous testing for safety and efﬁcacy of herbal supplements before they sold
over-the-counter (OTC). Pharmacovigilance on herbal supplements is still not well established.
Sexual enhancing herbals are on demand in men health but informal adulteration is growing issue
of concern. Recently, increase in use of herbal supplements for erectile dysfunction has laid a path
for many illegal compositions. This paper explores facts and evidences that were observed in
116 A.S. Bhagavathula et al.different countries attempting to demonstrate the importance of strengthening regulatory system to
strengthen the application of pharmacovigilance principles on sexual enhancing supplements. We
hereby explore the problem of sexual herbal supplements from pharmacovigilance perspectives.
We provide insights into the various concerns and call for collaboration to resolve the problem.
We highly recommend to include herbal medicines in national pharmacovigilance systems and to
establish comprehensive national pharmacovigilance program to raise the awareness about herbal
medicines particularly those used in enhancing sexual desire.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Rapid communication
1.1. Background
Pharmacovigilance is deﬁned as the study of the safety of mar-
keted drugs under the practical conditions of clinical usage in
large communities (Mann and Andrews, 2002). The use of her-
bal medicines continues to expand rapidly across the world and
many people show positive interest to use herbal products for
their health. The safety of herbal supplements has become a
globally major concern in the national and international health
authorities due to increasing adverse events and adulterations
(World Health Organisation, 2004). It is difﬁcult to analyse
the herbal products that cause adverse events due to lack of
sufﬁcient information and expertise. Inadequate regulatory
measures, weak quality control system and uncontrolled
distribution channels are some of the reasons that enhance the
market of herbal supplements (Shaw et al., 2012) (see Table 1).
1.2. The problem
In recent years, the unfulﬁlled desire for sex has been a subject
that has aroused increased public interest with respect to
improved sexual functions. The use of herbal medicines sub-
stantially increased due to escalated prevalence and impact
of sexual problems worldwide and estimates predicting the
incidence to raise over 320 million by the year 2025 (Aytac
et al., 1999).
1.3. Insights of reasons and causes
The various reasons to use herbal supplements in men may be
due to experiencing changes in erectile dysfunction (ED) due to
certain medical conditions such as diabetes and hypertension
and bodily changes as a normal part of life and aging (Potts
et al., 2006). The other reasons may be attributed to unwilling
to discuss such issues with doctors and disliking drug-mediated
erections (Choi et al., 2012). Many herbal supplements are
claimed to beneﬁt men seeking to enhance erectile function
and performance. These remedies often claim to be safe and
effective yet often adulterated with some of the pharmaceutical
ingredients and their analogues (e.g., sildenaﬁl-Viagra).
1.4. Implications of herbal sex remedies on consumers
This practice is illegal and places consumers at risk for poten-
tially serious side effects from these drugs such as abnormal
vision, headaches, myalgia, dizziness, ﬂushing and dyspepsia
(Clewell et al., 2010), and may lead to death. People usingPhosphodiesterase type 5 (PDE-5) inhibitors mainly suffer
from erectile dysfunction (ED).
The use of such remedies is associated with side effects and
drug–drug interactions as these persons may have co-morbid
conditions as diabetes and cardiovascular diseases and taking
numerous medications and denoted by poly-pharmacy.
In order to avoid these adverse consequences some patients
turn to natural products such as herbal supplements. (United
States Food and Drug Administration, 2006a). The United
States-US Food and Drug Administration (FDA) reports sug-
gest that more than one-third of herbal dietary supplements
marketed for sexual enhancement purchased on the internet
and store shelves are affected (United States Food and Drug
Administration, 2008). Many consumers perceive these prod-
ucts as completely safe because they often sold with labelling,
suggesting that they are natural ingredients that have been
approved by FDA for treating ED (Shamloul, 2010; Shah
et al., 2012). Lack of adequate evidence, no evaluation, and
absence of any regulatory obligations undertake rigorous test-
ing for safety and efﬁcacy of herbal supplements before they
sold over-the-counter (OTC). There are also risks attendant
upon self-medications and unmonitored use of these herbal
products. Due to consumer huge demand and lack of strong
pharmacovigilance these adulterated herbal products are
widely marketed in the world.
A recent report from the Internet and Health Fraud Team
survey claims one-third of the purchased ‘‘dietary supple-
ments’’ asserts spur sexual enhancement containing sildenaﬁl
or vardenaﬁl as active ingredient (Food and Drug
Administration, 2012). Other example, Rock Hard for Men
(with unknown manufacturer) marketed as natural supplement
in Australia contains two potent PDE-5 inhibitors and a sul-
fonylurea, glyburide (Australian Government, 2012). One
study in Singapore found that 77% of ‘‘natural’’ sex supple-
ments collection from informal markets containing undeclared
pharmaceuticals and more than half of them contains greater
than therapeutic dosages of pharmaceutical adulterants (Low
et al., 2009). This study also highlighted that 18% of sexual
enhancement supplements adulterated with lidocaine,
naproxen and chloramphenicol. Alarmingly, in a Netherlands
study nearly 75% of sexual enhancing supplements contain
experimental drugs (Venhuis and de Kaste, 2012).
Studies on some of the natural supplements such as
Yohimbine, Ginseng and Maca to regain the sexual vigour are
burdened with serious adverse effects. (American Urological
Association, 2014; Shin et al., 2010; Jang et al., 2008). A system-
atic review by Ernst and associates on yohimbine recorded seri-
ous adverse effects but the incidence was low, similarly with red
Ginseng (Ernst et al., 2006). Therefore, it is questionable
whether the beneﬁts of these herbal supplements outweigh its
Table 1 Causality categories: The causality categories described by the Uppsala Monitoring Centre.
1 Certain A clinical event, including laboratory test abnormality, occurring in a plausible time relationship to drug
administration, and which cannot be explained by concurrent disease or other drugs or chemicals. The response to
withdrawal of the drugs (dechallenge) should be clinically plausible. The event must be deﬁnitive pharmacologically or
phenomenologically, using a satisfactory rechallenge procedure if necessary
2 Probably/likely A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug,
unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable
response on withdrawal (dechallenge). Rechallenge information is not required to fulﬁl this deﬁnition
3 Possible A clinical event, including laboratory test abnormality, with a reasonable time sequence to administrations of the
drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug
withdrawal may be lacking or unclear
4 Unlikely A clinical event, including laboratory test abnormality, with a temporal relationship to drug administration which
makes a causal relationship improbable, and in which other drugs, chemicals or underlying disease provides plausible
explanations
5 Conditional/unclassiﬁed A clinical event, including laboratory test abnormality, reported as an adverse reaction, about which more data are
essential for a proper assessment, or the additional data are under examination
6 Unassessable/unclassiﬁable A report suggesting an adverse reaction which cannot be judged because information is insuﬃcient or contradictory,
and which cannot be supplemented or veriﬁed
As a step towards harmonization in drug regulation in the countries of the European Union (EU), three causality categories were proposed by the EU pharmacovigilance working parties
Category A ‘‘Reports including good reasons and suﬃcient documentation to assume a causal relationship, in the sense of
plausible, conceivable, likely, but not necessarily highly probable’’
Category B ‘‘Reports containing suﬃcient information to accept the possibility of a causal relationship, in the sense of not
impossible and not unlikely, although the connection is uncertain and may be even doubtful, e.g. because of missing
data, insuﬃcient evidence or the possibility of another explanation’’



























118 A.S. Bhagavathula et al.risk. In particular, all these studies were supported by manufac-
turers and are vulnerable to a degree of possible bias. This may
be one concern; therefore, the conclusions generated by them
may be false-positive.
1.5. The pharmacovigilance program on herbal remedies
The current laws regulating sexual enhancing supplements
assume that all supplements are safe until the dozens of deaths
are reported due to adverse events. The identiﬁcation of the
new ingredients in these supplements is a complex and time
consuming task, and regulatory authorities act only after the
prolonged exposure of consumers to these tainted supple-
ments. Cohen and co-workers described that clinicians should
advise patients that there are only two types of products avail-
able: (1) those that might be safe but do not work and (2) those
that might work but are not safe (Cohen and Venhuis, 2013).
Therefore, patients should be counselled by their pharmacists
to avoid these unsafe remedies before selling them. Global reg-
ulatory authorities should collaborate to create a global data-
base of identiﬁed adulterated products with their analytical
techniques to permit swift identiﬁcation of illegal products. It
should be kept in mind that a number of men are at risk of
yielding to the temptation of using these supplements for
improving their sexual functions.
Furthermore, regulatory authorities should apply a strong
pharmacovigilance program to monitor herbal products. The
campaign may take the form of advertising in media and
implementation of standard operation procedures (SOPs).
To assess an extensive array of toxicological evidence of
herbal supplements pharmacovigilance safety programs should
be adopted. Identifying the causes behind the public use of
herbal medicines in enhancing sexual desire, may underline
the strategies needed to implement global pharmacovigilance
system.
2. Conclusions
There is a high concern about the use of sexual herbal reme-
dies. The problem is of complex origin with safety and health
impact on public. Pharmacovigilance regulation of the trading
of sex herbal remedies is of paramount importance. The phar-
macological bases of such remedies to boost libido need to be
explored. The concerns are not about whether it works but to
delve deeper how it works.
The safety proﬁle of such remedies is of major concern.
Studies and multifaceted research are needed and scientiﬁc
evidence-based herbal remedies to support their utility are
deemed to support the legal authorities establishing a pharma-
covigilance surveillance programs to govern the marketing of
sexual herbal remedies.3. Recommendations
We highly recommend to include herbal medicines in active
national pharmacovigilance systems surveillance programs
and to establish comprehensive national pharmacovigilance
program to raise the awareness about herbal medicines partic-
ularly those used in enhancing sexual desire.References
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